CSF3 and neutropenia: In the present study, FN was observed in 8% in line with the CHARRTED trial; however, severe neutropenia (CTCAE≧Grade3) was observed in 49% more than the CHARRTED trial despite the primary prophylaxis with G-CSF in some patients.